ArticleOncotarget2017

Utilizing combinatorial engineering to develop Tie2 targeting antagonistic angiopoetin-2 ligands as candidates for anti-angiogenesis therapy.

Tomer Shlamkovich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.